Synaptic dysfunction in human immunodeficiency virus type-1-positive subjects: Inflammation or impaired neuronal plasticity?

Journal of Internal Medicine

Volumn 273, Issue 5, 2013, Pages 454-465

  Avdoshina, V ^a   Bachis, A ^a   Mocchetti, I ^a  

^a GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Apoptosis; Drug abuse; Gp120; NeuroAIDS; P75NTR; ProBDNF

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; BRAIN DERIVED NEUROTROPHIC FACTOR RECEPTOR; HLA ANTIGEN; NEUROTROPHIN RECEPTOR P75;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ALLELE; CEREBROSPINAL FLUID; CLINICAL FEATURE; DISEASE COURSE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV ASSOCIATED DEMENTIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; NERVE CELL PLASTICITY; NERVOUS SYSTEM INFLAMMATION; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW;

AIDS DEMENTIA COMPLEX; AXONAL TRANSPORT; BRAIN-DERIVED NEUROTROPHIC FACTOR; EVIDENCE-BASED MEDICINE; GENE EXPRESSION REGULATION, VIRAL; HIV SEROPOSITIVITY; HIV-1; HUMANS; INFLAMMATION; NERVE TISSUE PROTEINS; NEURONAL PLASTICITY; RECEPTOR, TRKB; RECEPTORS, NERVE GROWTH FACTOR; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SYNAPSES; SYNAPTIC TRANSMISSION;

EID: 84876733369     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/joim.12050     Document Type: Review

References (142)

1. http://www.unaids.org/en/Resources/.
2. Lucas S. Causes of death in the HAART era. Curr Opin Infect Dis 2012; 25: 36-41.
3. Green TC, McGowan SK, Yokell MA, Pouget ER, Rich JD. HIV infection and risk of overdose: a systematic review and meta-analysis. Aids 2012; 26: 403-17.
4. Scarlatti G, Tresoldi E, Bjorndal A et al. In vivo evolution of HIV-1 co-receptor usage and sensitivity to chemokine-mediated suppression. Nat Med 1997; 3: 1259-65.
5. Dean M, Carrington M, Winkler C et al. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Hemophilia Growth and Development Study, Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort Study, San Francisco City Cohort, ALIVE Study. Science 1996; 273: 1856-62.
6. Paxton WA, Martin SR, Tse D et al. Relative resistance to HIV-1 infection of CD4 lymphocytes from persons who remain uninfected despite multiple high-risk sexual exposure. Nat Med 1996; 2: 412-7.
7. Samson M, Libert F, Doranz BJ et al. Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature 1996; 382: 722-5.
8. Martin MP, Gao X, Lee JH et al. Epistatic interaction between KIR3DS1 and HLA-B delays the progression to AIDS. Nat Genet 2002; 31: 429-34.
9. Bissel SJ, Wiley CA. Human immunodeficiency virus infection of the brain: pitfalls in evaluating infected/affected cell populations. Brain Pathol 2004; 14: 97-108.
10. McArthur JC, Steiner J, Sacktor N, Nath A. Human immunodeficiency virus-associated neurocognitive disorders: mind the gap. Ann Neurol 2010; 67: 699-714.
11. Gonzalez-Scarano F, Martin-Garcia J. The neuropathogenesis of AIDS. Nat Rev Immunol 2005; 5: 69-81.
12. Ellis R, Langford D, Masliah E. HIV and antiretroviral therapy in the brain: neuronal injury and repair. Nat Rev Neurosci 2007; 8: 33-44.
13. Garden GA, Budd SL, Tsai E et al. Caspase cascades in human immunodeficiency virus-associated neurodegeneration. J Neurosci 2002; 22: 4015-24.
14. Gelbard HA, Epstein LG. HIV-1 encephalopathy in children. Curr Opin Pediatr 1995; 7: 655-62.
15. Joska JA, Gouse H, Paul RH, Stein DJ, Flisher AJ. Does highly active antiretroviral therapy improve neurocognitive function? A systematic review. J Neurovirol 2010; 16: 101-14.
16. McArthur JC, Haughey N, Gartner S et al. Human immunodeficiency virus-associated dementia: an evolving disease. J Neurovirol 2003; 9: 205-21.
17. Becker JT, Maruca V, Kingsley LA et al. Factors affecting brain structure in men with HIV disease in the post-HAART era. Neuroradiology 2012; 54: 113-21.
18. Cherner M, Ellis RJ, Lazzaretto D et al. Effects of HIV-1 infection and aging on neurobehavioral functioning: preliminary findings. Aids 2004; 18(Suppl 1): S27-34.
19. Baheti G, King JR, Acosta EP, Fletcher CV. Age-related differences in plasma and intracellular tenofovir concentrations in HIV-1-infected children, adolescents and adults. Aids 2013; 27: 221-5.
20. Masliah E, DeTeresa RM, Mallory ME, Hansen LA. Changes in pathological findings at autopsy in AIDS cases for the last 15 years. Aids 2000; 14: 69-74.
21. Resnick L, Berger JR, Shapshak P, Tourtellotte WW. Early penetration of the blood-brain-barrier by HIV. Neurology 1988; 38: 9-14.
22. James HJ, Sharer LR, Zhang Q et al. Expression of caspase-3 in brains from paediatric patients with HIV-1 encephalitis. Neuropathol Appl Neurobiol 1999; 25: 380-6.
23. Gray F, Adle-Biassette H, Chretien F, Lorin de la Grandmaison G, Force G, Keohane C. Neuropathology and neurodegeneration in human immunodeficiency virus infection. Pathogenesis of HIV-induced lesions of the brain, correlations with HIV-associated disorders and modifications according to treatments. Clin Neuropathol 2001; 20: 146-55.
24. Aylward EH, Henderer JD, McArthur JC et al. Reduced basal ganglia volume in HIV-1-associated dementia: results from quantitative neuroimaging. Neurology 1993; 43: 2099-104.
25. Berger JR, Arendt G. HIV dementia: the role of the basal ganglia and dopaminergic systems. J Psychopharmacol 2000; 14: 214-21.
26. Wang J, Yuan W, Li MD. Genes and pathways co-associated with the exposure to multiple drugs of abuse, including alcohol, amphetamine/methamphetamine, cocaine, marijuana, morphine, and/or nicotine: a review of proteomics analyses. Mol Neurobiol 2011; 44: 269-86.
27. Anderson E, Zink W, Xiong H, Gendelman HE. HIV-1-associated dementia: a metabolic encephalopathy perpetrated by virus-infected and immune-competent mononuclear phagocytes. J Acquir Immune Defic Syndr 2002; 31(Suppl 2): S43-54.
28. Everall IP, Hansen LA, Masliah E. The shifting patterns of HIV encephalitis neuropathology. Neurotox Res 2005; 8: 51-61.
29. Wiley CA, Achim C. Human immunodeficiency virus encephalitis is the pathological correlate of dementia in acquired immunodeficiency syndrome. Ann Neurol 1994; 36: 673-6.
30. Bezzi P, Domercq M, Brambilla L et al. CXCR4-activated astrocyte glutamate release via TNFalpha: amplification by microglia triggers neurotoxicity. Nat Neurosci 2001; 4: 702-10.
31. Kaul M, Garden GA, Lipton SA. Pathways to neuronal injury and apoptosis in HIV-associated dementia. Nature 2001; 410: 988-94.
32. Langford D, Sanders VJ, Mallory M, Kaul M, Masliah E. Expression of stromal cell-derived factor 1alpha protein in HIV encephalitis. J Neuroimmunol 2002; 127: 115-26.
33. Bachis A, Mocchetti I. The chemokine receptor CXCR4 and not the N-methyl-d-aspartate receptor mediates gp120 neurotoxicity in cerebellar granule cells. J Neurosci Res 2004; 75: 75-82.
34. Kaul M, Lipton SA. Chemokines and activated macrophages in HIV gp120-induced neuronal apoptosis. Proc Natl Acad Sci U S A 1999; 96: 8212-6.
35. Meucci O, Fatatis A, Simen AA, Bushell TJ, Gray PW, Miller RJ. Chemokines regulate hippocampal neuronal signaling and gp120 neurotoxicity. Proc Natl Acad Sci U S A 1998; 95: 14500-5.
36. Masliah E. Mechanisms of synaptic dysfunction in Alzheimer's disease. Histol Histopathol 1995; 10: 509-19.
37. Gatignol A. Transcription of HIV: Tat and cellular chromatin. Adv Pharmacol 2007; 55: 137-59.
38. Ensoli B, Buonaguro L, Barillari G et al. Release, uptake, and effects of extracellular human immunodeficiency virus type 1 Tat protein on cell growth and viral transactivation. J Virol 1993; 67: 277-87.
39. Chen P, Mayne M, Power C, Nath A. The Tat protein of HIV-1 induces tumor necrosis factor-alpha production. Implications for HIV-1-associated neurological diseases. J Biol Chem 1997; 272: 22385-8.
40. Kruman I, Nath A, Mattson MP. HIV-1 protein Tat induces apoptosis of hippocampal neurons by a mechanism involving caspase activation, calcium overload, and oxidative stress. Exp Neurol 1998; 154: 276-88.
41. Haughey NJ, Nath A, Mattson MP, Slevin JT, Geiger JD. HIV-1 Tat through phosphorylation of NMDA receptors potentiates glutamate excitotoxicity. J Neurochem 2001; 78: 457-67.
42. Li W, Li G, Steiner J, Nath A. Role of Tat protein in HIV neuropathogenesis. Neurotox Res 2009; 16: 205-20.
43. Matarrese P, Malorni W. Human immunodeficiency virus (HIV)-1 proteins and cytoskeleton: partners in viral life and host cell death. Cell Death Differ 2005; 12(Suppl 1): 932-41.
44. Nomaguchi M, Fujita M, Adachi A. Role of HIV-1 Vpu protein for virus spread and pathogenesis. Microbes Infect 2008; 10: 960-7.
45. Patel CA, Mukhtar M, Pomerantz RJ. Human immunodeficiency virus type 1 Vpr induces apoptosis in human neuronal cells. J Virol 2000; 74: 9717-26.
46. van de Bovenkamp M, Nottet HS, Pereira CF. Interactions of human immunodeficiency virus-1 proteins with neurons: possible role in the development of human immunodeficiency virus-1-associated dementia. Eur J Clin Invest 2002; 32: 619-27.
47. Dittmar MT, McKnight A, Simmons G, Clapham PR, Weiss RA, Simmonds P. HIV-1 tropism and co-receptor use. Nature 1997; 385: 495-6.
48. Bagetta G, Corasaniti MT, Berliocchi L, Navarra M, Finazzi-Agro A, Nistico G. HIV-1 gp120 produces DNA fragmentation in the cerebral cortex of rat. Biochem Biophys Res Commun 1995; 211: 130-6.
49. Biard-Piechaczyk M, Robert-Hebmann V, Richard V, Roland J, Hipskind RA, Devaux C. Caspase-dependent apoptosis of cells expressing the chemokine receptor CXCR4 is induced by cell membrane-associated human immunodeficiency virus type 1 envelope glycoprotein (gp120). Virology 2000; 268: 329-44.
50. Melli G, Keswani SC, Fischer A, Chen W, Hoke A. Spatially distinct and functionally independent mechanisms of axonal degeneration in a model of HIV-associated sensory neuropathy. Brain 2006; 129: 1330-8.
51. Everall IP, Bell C, Mallory M et al. Lithium ameliorates HIV-gp120-mediated neurotoxicity. Mol Cell Neurosci 2002; 21: 493-501.
52. Iskander S, Walsh KA, Hammond RR. Human CNS cultures exposed to HIV-1 gp120 reproduce dendritic injuries of HIV-1-associated dementia. J Neuroinflammation 2004; 1: 7.
53. Masliah E, Heaton RK, Marcotte TD et al. Dendritic injury is a pathological substrate for human immunodeficiency virus-related cognitive disorders. HNRC Group. The HIV Neurobehavioral Research Center. Ann Neurol 1997; 42: 963-72.
54. Toggas SM, Masliah E, Rockenstein EM, Rall GF, Abraham CR, Mucke L. Central nervous system damage produced by expression of the HIV-1 coat protein gp120 in transgenic mice. Nature 1994; 367: 188-93.
55. Pearson-Fuhrhop KM, Burke E, Cramer SC. The influence of genetic factors on brain plasticity and recovery after neural injury. Curr Opin Neurol 2012; 25: 682-8.
56. Huang EJ, Reichardt LF. Neurotrophins: roles in neuronal development and function. Annu Rev Neurosci 2001; 24: 677-736.
57. Levi-Montalcini R. The nerve growth factor 35 years later. Science 1987; 237: 1154-62.
58. Hofer M, Pagliusi SR, Hohn A, Leibrock J, Barde YA. Regional distribution of brain-derived neurotrophic factor mRNA in the adult mouse brain. EMBO J 1990; 9: 2459-64.
59. Maisonpierre PC, Belluscio L, Squinto S et al. Neurotrophin-3: a neurotrophic factor related to NGF and BDNF. Science 1990; 247: 1446-51.
60. Garofalo L, Ribeiro-da-Silva A, Cuello AC. Nerve growth factor-induced synaptogenesis and hypertrophy of cortical cholinergic terminals. Proc Natl Acad Sci U S A 1992; 89: 2639-43.
61. Patterson SL, Abel T, Deuel TA, Martin KC, Rose JC, Kandel ER. Recombinant BDNF rescues deficits in basal synaptic transmission and hippocampal LTP in BDNF knockout mice. Neuron 1996; 16: 1137-45.
62. Zakharenko SS, Patterson SL, Dragatsis I et al. Presynaptic BDNF required for a presynaptic but not postsynaptic component of LTP at hippocampal CA1-CA3 synapses. Neuron 2003; 39: 975-90.
63. Chen ZY, Jing D, Bath KG et al. Genetic variant BDNF (Val66Met) polymorphism alters anxiety-related behavior. Science 2006; 314: 140-3.
64. Huang ZJ, Kirkwood A, Pizzorusso T et al. BDNF regulates the maturation of inhibition and the critical period of plasticity in mouse visual cortex. Cell 1999; 98: 739-55.
65. Egan MF, Kojima M, Callicott JH et al. The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. Cell 2003; 112: 257-69.
66. Erickson KI, Prakash RS, Voss MW et al. Brain-derived neurotrophic factor is associated with age-related decline in hippocampal volume. J Neurosci 2010; 30: 5368-75.
67. Komulainen P, Pedersen M, Hanninen T et al. BDNF is a novel marker of cognitive function in ageing women: the DR's EXTRA Study. Neurobiol Learn Mem 2008; 90: 596-603.
68. Pezawas L, Verchinski BA, Mattay VS et al. The brain-derived neurotrophic factor val66met polymorphism and variation in human cortical morphology. J Neurosci 2004; 24: 10099-102.
69. Zuccato C, Cattaneo E. Brain-derived neurotrophic factor in neurodegenerative diseases. Nat Rev Neurol 2009; 5: 311-22.
70. Howells DW, Porritt MJ, Wong JY et al. Reduced BDNF mRNA expression in the Parkinson's disease substantia nigra. Exp Neurol 2000; 166: 127-35.
71. Nagatsu T, Mogi M, Ichinose H, Togari A. Changes in cytokines and neurotrophins in Parkinson's disease. J Neural Transm Suppl 2000; 60: 277-90.
72. Zuccato C, Ciammola A, Rigamonti D et al. Loss of huntingtin-mediated BDNF gene transcription in Huntington's disease. Science 2001; 293: 493-8.
73. Durany N, Thome J. Neurotrophic factors and the pathophysiology of schizophrenic psychoses. Eur Psychiatry 2004; 19: 326-37.
74. Scheff SW, Price DA. Alzheimer's disease-related alterations in synaptic density: neocortex and hippocampus. J Alzheimers Dis 2006; 9: 101-15.
75. Phillips HS, Hains JM, Armanini M, Laramee GR, Johnson SA, Winslow JW. BDNF mRNA is decreased in the hippocampus of individuals with Alzheimer's disease. Neuron 1991; 7: 695-702.
76. Laske C, Stransky E, Leyhe T et al. BDNF serum and CSF concentrations in Alzheimer's disease, normal pressure hydrocephalus and healthy controls. J Psychiatr Res 2007; 41: 387-94.
77. Driscoll I, Martin B, An Y et al. Plasma BDNF is associated with age-related white matter atrophy but not with cognitive function in older, non-demented adults. PLoS ONE 2012; 7: e35217.
78. Nagahara AH, Merrill DA, Coppola G et al. Neuroprotective effects of brain-derived neurotrophic factor in rodent and primate models of Alzheimer's disease. Nat Med 2009; 15: 331-7.
79. Avdoshina V, Garzino-Demo A, Bachis A et al. HIV-1 decreases the levels of neurotrophins in human lymphocytes. Aids 2011; 25: 1126-8.
80. Aloe L, Simone MD, Properzi F. Nerve growth factor: a neurotrophin with activity on cells of the immune system. Microsc Res Tech 1999; 45: 285-91.
81. Tessarollo L. Pleiotropic functions of neurotrophins in development. Cytokine Growth Factor Rev 1998; 9: 125-37.
82. Bachis A, Avdoshina V, Zecca L, Parsadanian M, Mocchetti I. Human immunodeficiency virus type 1 alters brain-derived neurotrophic factor processing in neurons. J Neurosci 2012; 32: 9477-84.
83. Nosheny RL, Bachis A, Acquas E, Mocchetti I. Human immunodeficiency virus type 1 glycoprotein gp120 reduces the levels of brain-derived neurotrophic factor in vivo: potential implication for neuronal cell death. Eur J Neurosci 2004; 20: 2857-64.
84. Bachis A, Cruz MI, Mocchetti I. M-tropic HIV envelope protein gp120 exhibits a different neuropathological profile than T-tropic gp120 in rat striatum. Eur J Neurosci 2010; 32: 570-8.
85. Lyons WE, Mamounas LA, Ricaurte GA et al. Brain-derived neurotrophic factor-deficient mice develop aggressiveness and hyperphagia in conjunction with brain serotonergic abnormalities. Proc Natl Acad Sci U S A 1999; 96: 15239-44.
86. Bachis A, Major EO, Mocchetti I. Brain-derived neurotrophic factor inhibits human immunodeficiency virus-1/gp120-mediated cerebellar granule cell death by preventing gp120 internalization. J Neurosci 2003; 23: 5715-22.
87. Nosheny RL, Ahmed F, Yakovlev A et al. Brain-derived neurotrophic factor prevents the nigrostriatal degeneration induced by human immunodeficiency virus-1 glycoprotein 120 in vivo. Eur J Neurosci 2007; 25: 2275-84.
88. Koliatsos VE, Mocchetti I. Trophic factors as therapeutic agents for diseases characterized by neuronal death. In: Koliatsos VE, Ratan RR, eds. Cell Death and Diseases of the Nervous System. Totowa, NJ: Humana Press Inc., 1999; 545-91.
89. Nagahara AH, Tuszynski MH. Potential therapeutic uses of BDNF in neurological and psychiatric disorders. Nat Rev Drug Discov 2011; 10: 209-19.
90. Ramirez SH, Sanchez JF, Dimitri CA, Gelbard HA, Dewhurst S, Maggirwar SB. Neurotrophins prevent HIV Tat-induced neuronal apoptosis via a nuclear factor-kappaB (NF-kappaB)-dependent mechanism. J Neurochem 2001; 78: 874-89.
91. Dorsey SG, Renn CL, Carim-Todd L et al. In vivo restoration of physiological levels of truncated TrkB.T1 receptor rescues neuronal cell death in a trisomic mouse model. Neuron 2006; 51: 21-8.
92. Han BH, D'Costa A, Back SA et al. BDNF blocks caspase-3 activation in neonatal hypoxia-ischemia. Neurobiol Dis 2000; 7: 38-53.
93. Herbein G, Mahlknecht U, Batliwalla F et al. Apoptosis of CD8+ T cells is mediated by macrophages through interaction of HIV gp120 with chemokine receptor CXCR4. Nature 1998; 395: 189-94.
94. Hesselgesser J, Taub D, Baskar P et al. Neuronal apoptosis induced by HIV-1 gp120 and the chemokine SDF-1 alpha is mediated by the chemokine receptor CXCR4. Curr Biol 1998; 8: 595-8.
95. Bergami M, Rimondini R, Santi S, Blum R, Gotz M, Canossa M. Deletion of TrkB in adult progenitors alters newborn neuron integration into hippocampal circuits and increases anxiety-like behavior. Proc Natl Acad Sci U S A 2008; 105: 15570-5.
96. Tran PB, Miller RJ. HIV-1, chemokines and neurogenesis. Neurotox Res 2005; 8: 149-58.
97. Chao MV, Bothwell MA, Ross AH et al. Gene transfer and molecular cloning of the human NGF receptor. Science 1986; 232: 518-21.
98. Ross AH, Grob P, Bothwell M et al. Characterization of nerve growth factor receptor in neural crest tumors using monoclonal antibodies. Proc Natl Acad Sci U S A 1984; 81: 6681-5.
99. Rodriguez-Tebar A, Dechant G, Barde YA. Binding of brain-derived neurotrophic factor to the nerve growth factor receptor. Neuron 1990; 4: 487-92.
100. Brennan C, Rivas-Plata K, Landis SC. The p75 neurotrophin receptor influences NT-3 responsiveness of sympathetic neurons in vivo. Nat Neurosci 1999; 2: 699-705.
101. Hempstead BL, Martin-Zanca D, Kaplan DR, Parada LF, Chao MV. High-affinity NGF binding requires coexpression of the trk proto-oncogene and the low-affinity NGF receptor. Nature 1991; 350: 678-83.
102. Feinstein E, Kimchi A, Wallach D, Boldin M, Varfolomeev E. The death domain: a module shared by proteins with diverse cellular functions. Trends Biochem Sci 1995; 20: 342-4.
103. Gu C, Casaccia-Bonnefil P, Srinivasan A, Chao MV. Oligodendrocyte apoptosis mediated by caspase activation. J Neurosci 1999; 19: 3043-9.
104. Kenchappa RS, Zampieri N, Chao MV et al. Ligand-dependent cleavage of the P75 neurotrophin receptor is necessary for NRIF nuclear translocation and apoptosis in sympathetic neurons. Neuron 2006; 50: 219-32.
105. Park KJ, Grosso CA, Aubert I, Kaplan DR, Miller FD. p75NTR-dependent, myelin-mediated axonal degeneration regulates neural connectivity in the adult brain. Nat Neurosci 2010; 13: 559-66.
106. Carter BD, Kaltschmidt C, Kaltschmidt B et al. Selective activation of NF-kappa B by nerve growth factor through the neurotrophin receptor p75. Science 1996; 272: 542-5.
107. Salehi AH, Xanthoudakis S, Barker PA. NRAGE, a p75 neurotrophin receptor-interacting protein, induces caspase activation and cell death through a JNK-dependent mitochondrial pathway. J Biol Chem 2002; 277: 48043-50.
108. Coulson EJ, Reid K, Barrett GL, Bartlett PF. p75 neurotrophin receptor-mediated neuronal death is promoted by Bcl-2 and prevented by Bcl-xL. J Biol Chem 1999; 274: 16387-91.
109. Hauser KF, El-Hage N, Buch S et al. Impact of opiate-HIV-1 interactions on neurotoxic signaling. J Neuroimmune Pharmacol 2006; 1: 98-105.
110. Kaplan DR, Hempstead BL, Martin-Zanca D, Chao MV, Parada LF. The trk proto-oncogene product: a signal transducing receptor for nerve growth factor. Science 1991; 252: 554-8.
111. Kaplan DR, Miller FD. Neurotrophin signal transduction in the nervous system. Curr Opin Neurobiol 2000; 10: 381-91.
112. Chao MV, Hempstead BL. p75 and Trk: a two-receptor system. Trends Neurosci 1995; 18: 321-6.
113. Klein R, Nanduri V, Jing SA et al. The trkB tyrosine protein kinase is a receptor for brain-derived neurotrophic factor and neurotrophin-3. Cell 1991; 66: 395-403.
114. Schecterson LC, Bothwell M. Neurotrophin receptors: old friends with new partners. Dev Neurobiol 2010; 70: 332-8.
115. Carim-Todd L, Bath KG, Fulgenzi G et al. Endogenous truncated TrkB.T1 receptor regulates neuronal complexity and TrkB kinase receptor function in vivo. J Neurosci 2009; 29: 678-85.
116. Hempstead BL. The many faces of p75NTR. Curr Opin Neurobiol 2002; 12: 260-7.
117. Fahnestock M, Michalski B, Xu B, Coughlin MD. The precursor pro-nerve growth factor is the predominant form of nerve growth factor in brain and is increased in Alzheimer's disease. Mol Cell Neurosci 2001; 18: 210-20.
118. Yang J, Siao CJ, Nagappan G et al. Neuronal release of proBDNF. Nat Neurosci 2009; 12: 113-5.
119. Seidah NG, Benjannet S, Pareek S, Chretien M, Murphy RA. Cellular processing of the neurotrophin precursors of NT3 and BDNF by the mammalian proprotein convertases. FEBS Lett 1996; 379: 247-50.
120. Mowla SJ, Pareek S, Farhadi HF et al. Differential sorting of nerve growth factor and brain-derived neurotrophic factor in hippocampal neurons. J Neurosci 1999; 19: 2069-80.
121. Lee R, Kermani P, Teng KK, Hempstead BL. Regulation of cell survival by secreted proneurotrophins. Science 2001; 294: 1945-8.
122. Kaplan DR, Miller FD. Axon growth inhibition: signals from the p75 neurotrophin receptor. Nat Neurosci 2003; 6: 435-6.
123. Singh KK, Park KJ, Hong EJ et al. Developmental axon pruning mediated by BDNF-p75NTR-dependent axon degeneration. Nat Neurosci 2008; 11: 649-58.
124. Yang F, Je HS, Ji Y, Nagappan G, Hempstead B, Lu B. Pro-BDNF-induced synaptic depression and retraction at developing neuromuscular synapses. J Cell Biol 2009; 185: 727-41.
125. Woo NH, Teng HK, Siao CJ et al. Activation of p75NTR by proBDNF facilitates hippocampal long-term depression. Nat Neurosci 2005; 8: 1069-77.
126. Jansen P, Giehl K, Nyengaard JR et al. Roles for the pro-neurotrophin receptor sortilin in neuronal development, aging and brain injury. Nat Neurosci 2007; 10: 1449-57.
127. Nykjaer A, Lee R, Teng KK et al. Sortilin is essential for proNGF-induced neuronal cell death. Nature 2004; 427: 843-8.
128. Teng HK, Teng KK, Lee R et al. ProBDNF induces neuronal apoptosis via activation of a receptor complex of p75NTR and sortilin. J Neurosci 2005; 25: 5455-63.
129. Dobrowsky RT, Werner MH, Castellino AM, Chao MV, Hannun YA. Activation of the sphingomyelin cycle through the low-affinity neurotrophin receptor. Science 1994; 265: 1596-9.
130. Lievremont JP, Sciorati C, Morandi E et al. The p75(NTR)-induced apoptotic program develops through a ceramide-caspase pathway negatively regulated by nitric oxide. J Biol Chem 1999; 274: 15466-72.
131. Van Veldhoven PP, Matthews TJ, Bolognesi DP, Bell RM. Changes in bioactive lipids, alkylacylglycerol and ceramide, occur in HIV-infected cells. Biochem Biophys Res Commun 1992; 187: 209-16.
132. Haughey NJ, Cutler RG, Tamara A et al. Perturbation of sphingolipid metabolism and ceramide production in HIV-dementia. Ann Neurol 2004; 55: 257-67.
133. Obeid LM, Linardic CM, Karolak LA, Hannun YA. Programmed cell death induced by ceramide. Science 1993; 259: 1769-71.
134. Pelled D, Raveh T, Riebeling C et al. Death-associated protein (DAP) kinase plays a central role in ceramide-induced apoptosis in cultured hippocampal neurons. J Biol Chem 2002; 277: 1957-61.
135. Conant K, McArthur JC, Griffin DE, Sjulson L, Wahl LM, Irani DN. Cerebrospinal fluid levels of MMP-2, 7, and 9 are elevated in association with human immunodeficiency virus dementia. Ann Neurol 1999; 46: 391-8.
136. Coulson EJ. Does the p75 neurotrophin receptor mediate Abeta-induced toxicity in Alzheimer's disease? J Neurochem 2006; 98: 654-60.
137. Zuccato C, Marullo M, Conforti P, MacDonald ME, Tartari M, Cattaneo E. Systematic assessment of BDNF and its receptor levels in human cortices affected by Huntington's disease. Brain Pathol 2008; 18: 225-38.
138. Roux PP, Colicos MA, Barker PA, Kennedy TE. p75 neurotrophin receptor expression is induced in apoptotic neurons after seizure. J Neurosci 1999; 19: 6887-96.
139. Volosin M, Trotter C, Cragnolini A et al. Induction of proneurotrophins and activation of p75NTR-mediated apoptosis via neurotrophin receptor-interacting factor in hippocampal neurons after seizures. J Neurosci 2008; 28: 9870-9.
140. Lebrun-Julien F, Bertrand MJ, De Backer O et al. ProNGF induces TNF alpha-dependent death of retinal ganglion cells through a p75NTR non-cell-autonomous signaling pathway. Proc Natl Acad Sci U S A 2010; 107: 3817-22.
141. Bussmann KA, Sofroniew MV. Re-expression of p75NTR by adult motor neurons after axotomy is triggered by retrograde transport of a positive signal from axons regrowing through damaged or denervated peripheral nerve tissue. Neuroscience 1999; 91: 273-81.
142. Wu CK, Thal L, Pizzo D, Hansen L, Masliah E, Geula C. Apoptotic signals within the basal forebrain cholinergic neurons in Alzheimer's disease. Exp Neurol 2005; 195: 484-96.